Clinical Trial

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-04-16; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-07-16
Trial Details
NCT Number NCT06941857
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: NextCure, Inc., Lustgarten Foundation
Conditions Pancreatic Cancer
Enrollment 20 participants
Start Date 2025-09-04
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-05